Navigation Links
Lpath CEO, Scott Pancoast, to Present Live Online at RetailInvestorConferences.com on June 2 at 1 PM EDT
Date:5/26/2011

NEW YORK, May 26, 2011 /PRNewswire/ -- Lpath, Inc. (OTCBB: LPTN), the industry leader in lipidomics-based therapeutics, will present on RetailInvestorConferences.com on June 2, 2011 at 1:00 PM EDT.

Lpath's president and CEO, Scott Pancoast, will discuss the company's progress, including status updates on the PEDigree and Nexus clinical trials, where the company's ocular drug candidate, iSONEP™, is being investigated in human proof-of-concept studies.

To access, follow this link: www.retailinvestorconferences.com and then click on: "Register/Watch Event Now!" Attendees are advised to pre-register and receive event updates.

This will be a live, interactive online event where investors are invited to ask the company questions in real-time in the virtual "presentation hall." After the presentation investors are invited to ask questions and download shareholder materials from the company's "virtual booth." A replay of the event will be available for 90 days.

Lpath entered into an agreement with Pfizer in late 2010 that provides Pfizer an exclusive option for a worldwide license to develop and commercialize iSONEP for ocular indications. Pfizer and Lpath are collaborating closely on the two iSONEP clinical trials.

Pfizer also has a right of first refusal, which expires in late 2013, for Lpath's cancer drug candidate, ASONEP™. Lpath is planning to further investigate ASONEP in a Phase 2 trial involving renal cell carcinoma patients and perhaps in a second trial involving patients with prostate cancer or neuroblastoma.

About Lpath

San Diego-based Lpath, a therapeutic antibody company, is the category leader in lipidomics-based therapeutics, an emerging field of medicine that targets bioactive signaling lipids for treating a wide range of human disease. Lpath's ImmuneY2™ drug-discovery engine has the unique ability to generate therapeutic antibodies that bind to and inhibit bioactive lipids that contribute to disease. The company has developed three drug candidates, two of which -- iSONEP for wet AMD and ASONEP for cancer -- have completed Phase 1 clinical trials. Lpath entered into an agreement with Pfizer in 2010 that provides Pfizer an exclusive option for a worldwide license to develop and commercialize iSONEP. For more information, visit www.Lpath.com.

About RetailInvestorConferences.com

RetailInvestorConferences.com, created by BetterInvesting (NAIC), PR Newswire and MUNCmedia, is the first monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with retail investors using a graphically-enhanced online platform.

Designed to replicate the look and feel of location-based investor conferences, Retail Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network and MUNCmedia's sophisticated retail investor targeting.

Forward-Looking Statements

The Company cautions you that the statements included in this press release that are not a description of historical facts are forward-looking statements. These include statements regarding: the eventual commercial viability of the Company's drug programs; the eventual revenues that the Company would attain if the drug eventually gets approved. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in the Company's business, including, without limitation: the results of any future clinical trials for iSONEP may not be favorable and the Company may never receive regulatory approval for iSONEP; and the Company may not be able to secure the funds necessary to support its clinical trial and product development plans. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q filed with the SEC. Such documents may be read free of charge on the SEC's web site at www.sec.gov. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.


'/>"/>
SOURCE Lpath, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
2. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
3. Technest Holdings, Inc. to Acquire AccelPath, LLC; Issue Contingent Value Rights to Common Stockholders; and Issue Shares of Its Series E 5% Convertible Preferred Stock
4. Lpath, Inc. CEO to Present Live, Online at RetailInvestorConferences.com on May 5th
5. Lpath, Inc. CEO Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
6. Ancestry.com DNA Testing Reveals Roots Authors Scottish Ancestry
7. Scottsdale Facility to Be First in U.S. to Showcase True REST Technology
8. Potential Skin Cancer Breakthrough Tested at Scottsdale Healthcare Published Today in New England Journal of Medicine
9. Vanda Pharmaceuticals Announces Expiration of Hart-Scott -Rodino Waiting Period for Exclusive License of Fanapt(TM)
10. Scott Glenn Joins Exagen Diagnostics as Chairman and CEO
11. Hill-Rom Appoints Scott Jeffers as Senior Vice President, Global Supply Chain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)...  Glenmark Pharmaceuticals, a global pharmaceutical company, today ... fixed-dose combination of mometasone furoate (25 mcg) and ... nasal spray being studied for the treatment of ... recently completed Phase 3 trial assessing the efficacy ... mometasone, olopatadine or placebo. "We continue ...
(Date:3/29/2017)... 29, 2017 Transparency Market ... provides an exhaustive study of the U.S. substance abuse ... companies are functional in this market at present, ... leading companies, such as GlaxoSmithKline Plc., Pfizer Inc., ... on various marketing strategies to increase their visibility, ...
(Date:3/29/2017)... Research and Markets has announced the addition of the "Global ... ... market to grow at a CAGR of 2.87% during the period ... has been prepared based on an in-depth market analysis with inputs ... growth prospects over the coming years. The report also includes a ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... 2017 , ... An inventor from Raynham, Mass., knows the ... conjunction with my braces always rubbed against the inside of my cheeks, causing ... problem." The O.B.S. was the result of his brainstorming. , This patent-pending invention ...
(Date:3/29/2017)... ... 29, 2017 , ... The assembly of synthetic DNA has ... repetitive steps and often scientists require many different versions of DNA. Therefore, this ... in a lower error rate and cost saving for reagents and consumables. , ...
(Date:3/29/2017)... North Hollywood, CA (PRWEB) , ... March 29, 2017 , ... ... and Northridge , is now offering laser dental treatments. Dental lasers are safe ... treatments. Laser dentistry expands patients’ options and can improve the overall quality of care. ...
(Date:3/29/2017)... , ... March 29, 2017 , ... ... Gastrointestinal Oncology™ (SOGO™), a specialized continuing medical education conference for clinicians who manage ... Intercontinental Time Square, New York. , The program will be led by ...
(Date:3/29/2017)... ... March 29, 2017 , ... AvePoint , the Microsoft Cloud expert, ... in Richmond, Virginia, located at the Riverfront Plaza, 901 East Byrd Street. AvePoint is ... Virginia Ralph S. Northam and Mayor of Richmond Levar M. Stoney. , Founded in ...
Breaking Medicine News(10 mins):